WO2020186111A3 - Anticorps se liant à vista et leurs utilisations - Google Patents

Anticorps se liant à vista et leurs utilisations Download PDF

Info

Publication number
WO2020186111A3
WO2020186111A3 PCT/US2020/022476 US2020022476W WO2020186111A3 WO 2020186111 A3 WO2020186111 A3 WO 2020186111A3 US 2020022476 W US2020022476 W US 2020022476W WO 2020186111 A3 WO2020186111 A3 WO 2020186111A3
Authority
WO
WIPO (PCT)
Prior art keywords
vista
binding antibodies
antibodies
cancer
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2020/022476
Other languages
English (en)
Other versions
WO2020186111A2 (fr
Inventor
Ryan Lewis KELLY
Nishant METHA
Jennifer R. Cochran
Sainiteesh MADDINENI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
xCella Biosciences Inc
Original Assignee
Leland Stanford Junior University
xCella Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University, xCella Biosciences Inc filed Critical Leland Stanford Junior University
Publication of WO2020186111A2 publication Critical patent/WO2020186111A2/fr
Publication of WO2020186111A3 publication Critical patent/WO2020186111A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des procédés thérapeutiques d'utilisation d'anticorps anti-VISTA dans le traitement de maladies telles que le cancer.
PCT/US2020/022476 2019-03-12 2020-03-12 Anticorps se liant à vista et leurs utilisations Ceased WO2020186111A2 (fr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201962817242P 2019-03-12 2019-03-12
US62/817,242 2019-03-12
US201962828259P 2019-04-02 2019-04-02
US62/828,259 2019-04-02
US201962869507P 2019-07-01 2019-07-01
US62/869,507 2019-07-01
US201962914355P 2019-10-11 2019-10-11
US62/914,355 2019-10-11

Publications (2)

Publication Number Publication Date
WO2020186111A2 WO2020186111A2 (fr) 2020-09-17
WO2020186111A3 true WO2020186111A3 (fr) 2020-10-15

Family

ID=72427103

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/022476 Ceased WO2020186111A2 (fr) 2019-03-12 2020-03-12 Anticorps se liant à vista et leurs utilisations

Country Status (1)

Country Link
WO (1) WO2020186111A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240101630A1 (en) * 2020-12-18 2024-03-28 Cullinan Amber Corp. Bi-functional linear fusion collagen-localized immunomodulatory molecules and methods thereof
GB202108446D0 (en) * 2021-06-14 2021-07-28 Hummingbird Bioscience Holdings Pte Ltd Cells expressing VISTA antigen-binding molecules

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110287002A1 (en) * 2010-05-04 2011-11-24 Adimab, Llc Antibodies against epidermal growth factor receptor (egfr) and uses thereof
US20140271617A1 (en) * 2011-09-30 2014-09-18 Chugai Seiyaku Kabushiki Kaisha Ion concentration-dependent binding molecule library
WO2018027042A1 (fr) * 2016-08-03 2018-02-08 Bio-Techne Corporation Identification de vsig3/vista comme nouveau point de contrôle immunitaire et son utilisation en immunothérapie

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110287002A1 (en) * 2010-05-04 2011-11-24 Adimab, Llc Antibodies against epidermal growth factor receptor (egfr) and uses thereof
US20140271617A1 (en) * 2011-09-30 2014-09-18 Chugai Seiyaku Kabushiki Kaisha Ion concentration-dependent binding molecule library
WO2018027042A1 (fr) * 2016-08-03 2018-02-08 Bio-Techne Corporation Identification de vsig3/vista comme nouveau point de contrôle immunitaire et son utilisation en immunothérapie

Also Published As

Publication number Publication date
WO2020186111A2 (fr) 2020-09-17

Similar Documents

Publication Publication Date Title
WO2019224716A8 (fr) Anticorps spécifiques de gucy2c et leurs utilisations
PH12018502429A1 (en) Antibody molecules for cancer treatment
EP4295846A3 (fr) Hétéroarylaminopyrimidine amides inhibiteurs d'autophagie et leurs procédés d'utilisation
WO2018190719A3 (fr) Anticorps anti-sirp alpha
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
EP4566621A3 (fr) Protéines de liaison à dll3/cd3 pour le traitement du cancer
EP4603508A3 (fr) Anticorps anti-fzd et méthodes d'utilisation
CA3055791A1 (fr) Procedes de traitement
EP4442278A3 (fr) Anticorps humanisés dirigés contre c-kit
EP4421094A3 (fr) Agents thérapeutiques ciblés et leurs utilisation
NZ753515A (en) Methods for treatment of cancer comprising tigit-binding agents
MY207784A (en) Anti-cd73 antibodies
WO2019234241A8 (fr) Anticorps anti-oxmif/anti-cd3 pour le traitement de cancers
ZA202103867B (en) Tubulysins and protein-tubulysin conjugates
WO2019175198A3 (fr) Anticorps
WO2021181233A3 (fr) Protéines de fusion et leurs utilisations
WO2020036646A3 (fr) Néo-antigènes du cancer et leurs utilisations dans des vaccins contre le cancer et une immunothérapie anticancéreuse à base de tcr
WO2020180712A8 (fr) Anticorps anti-tnfr2 et leurs utilisations
WO2021207433A3 (fr) Épitopes d'anticorps neutralisant le sars-cov-2
EP4353320A3 (fr) Utilisation de plasma sanguin et fractions de plasma sanguin en tant que therapie pour lutter contre la croissance et la progression tumorale
MX2019008233A (es) Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral.
MX2021010766A (es) Anticuerpos que se unen a la proteína del gen 6 inducible por el factor de necrosis tumoral (tsg-6) y usos de estos.
WO2019094533A8 (fr) Agents de liaison à angptl8 et leurs méthodes d'utilisation
MX2023010661A (es) Moléculas de union al receptor leucocitario humano similar a inmunoglobulina b1 (lilrb1) y al receptor leucocitario humano similar a inmunoglobulina b2 (lilrb2) y usos para las mismas.
MX2021008507A (es) Moleculas que se unen al receptor leucocitario similar a inmunoglobulina subfamilia b miembro 3 (lilrb3) y usos para las mismas.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20770904

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20770904

Country of ref document: EP

Kind code of ref document: A2